NYSEAMERICAN:AZTR Azitra 8/14/2023 Earnings Report $0.28 -0.03 (-10.38%) Closing price 04/17/2025 04:10 PM EasternExtended Trading$0.28 0.00 (-1.40%) As of 08:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings History Azitra EPS ResultsActual EPS-$70.80Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAzitra Revenue ResultsActual Revenue$0.17 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAzitra Announcement DetailsQuarterDate8/14/2023TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsAzitra's next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Azitra Earnings HeadlinesAzitra to Present at Microbiome Times Partnering ForumMarch 12, 2025 | prnewswire.comAZTR: Netherton Topline Expected by Year-EndMarch 3, 2025 | msn.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 21, 2025 | Crypto Swap Profits (Ad)Maxim Group Reaffirms Their Buy Rating on Azitra Inc (AZTR)February 27, 2025 | markets.businessinsider.comAzitra, Inc. Announces Full Year 2024 Financial Results and Provides Business UpdatesFebruary 24, 2025 | gurufocus.comAzitra, Inc. Announces Full Year 2024 Financial Results and Provides Business UpdatesFebruary 24, 2025 | prnewswire.comSee More Azitra Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email. Email Address About AzitraAzitra (NYSEAMERICAN:AZTR), an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.View Azitra ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings ReportAlcoa’s Solid Earnings Don’t Make Tariff Math Easier for AA Stock3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
